Brief: Glaukos Announces Completion Of Patient Enrollment In Phase 2 Study Of Glk-321 For Demodex Blepharitis
25/06/2026 12:23
BRIEF-Glaukos Announces Completion Of Patient Enrollment In Phase 2 Study Of Glk-321 For Demodex Blepharitis June 25 (Reuters) - Glaukos Corp GKOS.N:
GLAUKOS ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE 2 STUDY OF GLK-321 FOR DEMODEX BLEPHARITIS
GLAUKOS ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE 2 STUDY OF GLK-321 FOR DEMODEX BLEPHARITIS
Source text: ID:nBw8jXZSWa
Further company coverage: GKOS.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Glaukos
See all newsGlaukos says late-stage eye disease treatment shows lasting benefits after single dose
Brief: Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes In Keratoconus
US RESEARCH ROUNDUP-Boeing, Twilio, WP Carey
U.S. RESEARCH ROUNDUP-Equinix, Meta, S&P Global
Glaukos Corp reports results for the quarter ended June 30 - Earnings Summary